Sanjay Chandriani is part of a @TargetALS_fdn-funded consortium investigating cryptic circular RNAs as biomarkers of TDP-43 dysfunction in #ALS. Better biomarkers mean getting the right therapy to the right person. Learn more about the $2.4M initiative. targetals.org/news/science-o…

At Trace, we're driven by a deeper understanding of the genetic drivers of ALS to make medicines for people with this disease. At the helm is CEO @ercgrn, who was honored as one of @GoldmanSachs most exceptional entrepreneurs at their Builders & Innovators Summit. Congrats, Eric!

Don't miss the Trace team at the 2026 #NEALSMtg! Visit us to check out posters from Terry Fang, Marjie Hard, and CMO Irina Antonijevic, who will also join a roundtable discussion. We look forward to connecting with the ALS community. Details below!

Last week, our team gathered in Napa for our annual company offsite. Between great conversations, planning for what's next and time to recharge, we left feeling connected and energized for the work ahead. We're always grateful for quality time together as a team.

Trace is proud to sponsor the @ALSTDI White Coat Affair Gala this weekend! Each year, the gala brings the ALS community together to recognize the progress being made toward ending this disease. Thank you to the ALS TDI for everything you do to advance #ALS research.

We're excited to share Terry Fang will present preclinical data on TRCN-1023, our ASO designed to restore UNC13A function in ALS, at the @OTSociety annual meeting in Denver on October 12. #OTS26

We were excited to join @youralsnetwork again this year for the annual Napa Valley Ride, Walk & Roll to Cure #ALS, joined by patients, caregivers, and advocates all working toward a cure for this devastating disease. Thank you to everyone who rode, walked, rolled, and showed up.

Emily Engel, Associate Director of Clinical Operations & Patient Advocacy, will present a poster exploring how partnering with patients & caregivers leads to more thoughtful clinical trial design at @alsassociation's #ALSNexus26 in Orlando. Learn more: als.org/get-involved/events/…

It was a great week at #BIO2026 in San Diego. Members of the Trace team connected with leaders across the life sciences ecosystem, and CBO @NMordwinkin joined fellow industry leaders for a panel discussion on lead asset focus and pipeline growth. Thank you for joining us!

Trace was proud to support the 2026 @youralsnetwork Champions for Cures and Care Gala as a Gold Sponsor. We enjoyed connecting with so many members of the ALS community whose dedication, grit and resilience inspire us every day. Thank you to the ALS Network for a great evening.

Today, we're excited to announce we have initiated the global clinical development program for TRCN-1023, an investigational antisense oligonucleotide designed to restore UNC13A protein function for the treatment of #ALS. CEO @ercgrn shares insight below. traceneuro.com/uncategorized…

We're heading to Madrid for #ENCALS2026! CMO Irina Antonijevic and VP, Translational Sciences @sanjayofSF will present posters highlighting Trace's ongoing ALS research and the Phase 1/2 FUNCtion ALS trial. Details on this year's congress: encals-congress.com/encals20…

We're looking forward to #BIO2026 in San Diego! Trace CBO & CSO @NMordwinkin will join industry leaders on June 22 for a discussion on balancing lead asset focus and pipeline potential in today's evolving biotech landscape. Learn more: convention.bio.org/2026-sess…

Trace CMO Irina Antonijevic is in Boston for the 5th annual #ALS Drug Development Summit this week! Find details about both her oral presentation and panel below, and learn more about this year's event here. als-drug-development.com/

CEO @ercgrn will join @biospace alongside @CityTx_'s Andy Orth and Kivu Bioscience's Mo Trikha for a NextGen webinar focused on elevating your organization as biotech makes a come back. Register to join us here! biospace.com/events/register…

To kick off #ALSAwarenessMonth, we had the privilege of welcoming Brian & Lori Andre to Trace. A truly extraordinary couple dedicated to making an impact in the fight against ALS through their mentorship and philanthropy, their words left us inspired and more motivated than ever.

We look forward to joining our #ALS network on the East Coast at the @TargetALS_fdn meeting this week! Preclinical Science lead Terry Fang will give an oral presentation on our latest research on the potential of UNC13A restoration as a treatment for people with ALS. More below.

We’re proud to share that CEO & co-founder @ercgrn has been named to @INVIVOnow's Rising Leaders! This list celebrates leaders shaping the future of health through bold thinking & meaningful impact, a vision Eric brings to advancing new approaches for ALS. insights.citeline.com/in-viv…